Keeping the Flu Away: Synthetic Protein Activates Immune System Within Two Hours

San Diego State University researchers at the Donald P. Shiley BioScience Center may have found the secret to helping the immune system fight off the flu before it gets you sick.

A new study published July 6 in the Public Library of Science journal PLoS ONE, finds that EP67, a powerful synthetic protein, is able to activate the innate immune system within just two hours of being administered.

Prior to this study, EP67 had been primarily used as an adjuvant for vaccines, something added to the vaccine to help activate the immune response. But Joy Phillips, Ph.D. a lead author of the study with her colleague Sam Sanderson, Ph.D. at the University of Nebraska Medical Center, saw potential for it to work on its own.

"The flu virus is very sneaky and actively keeps the immune system from detecting it for a few days until you are getting symptoms," Phillips said. "Our research showed that by introducing EP67 into the body within 24 hours of exposure to the flu virus caused the immune system to react almost immediately to the threat, well before your body normally would."

Because EP67 doesn't work on the virus but on the immune system itself, it functions the same no matter the flu strain, unlike the influenza vaccine which has to exactly match the currently circulating strain.

Phillips said while this study focuses on the flu, EP67 has the potential to work on other respiratory diseases and fungal infections and could have huge potential for emergency therapeutics.

"When you find out you've been exposed to the flu, the only treatments available now target the virus directly but they are not reliable and often the virus develops a resistance against them," Phillips said. "EP67 could potentially be a therapeutic that someone would take when they know they've been exposed that would help the body fight off the virus before you get sick."

It could even be used in the event of a new strain of infectious disease, before the actual pathogen has been identified, as in SARS or the 2009 H1N1 influenza outbreak, Phillips said.

Right now, the testing has been done primarily in mice by infecting them with a flu virus. Those that were given a dose of EP67 within 24 hours of the infection didn't get sick (or as sick) as those that were not treated with EP67.

The level of illness in mice is measured by weight loss. Typically, mice lose approximately 20 percent of their weight when they are infected with the flu but mice treated with EP67 lost an average of just six percent. More importantly, mice who were treated a day after being infected with a lethal dose of influenza did not die, Phillips said.

She said there are also huge implications for veterinary applications, since EP67 is active in animals, including birds.

Future research will examine the effect EP67 has in the presence of a number of other pathogens and to look closer at exactly how EP67 functions within different cells in the body.

Journal Reference:

1. Sam D. Sanderson, Marilyn L. Thoman, Kornelia Kis, Elizabeth L. Virts, Edgar B. Herrera, Stephanie Widmann, Homero Sepulveda, Joy A. Phillips. Innate Immune Induction and Influenza Protection Elicited by a Response-Selective Agonist of Human C5a. PLoS ONE, 2012; 7 (7): e40303 DOI: 10.1371/journal.pone.0040303

Courtesy: ScienceDaily